CDA | Evidence Driven
CDA | Evidence Driven

tofersen

Details

Generic Name:
tofersen
Project Status:
Pending
Therapeutic Area:
Amyotrophic lateral sclerosis (ALS)
Manufacturer:
Biogen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0883-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​Tofersen (injection) is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Tofersen (injection) is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 15, 2025